| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/18/2006 | US7078054 The capsule shell contains a migrateable component (other than glycerol) which is also present in the capsule filling. |
| 07/18/2006 | US7078053 Ibuprofen composition |
| 07/18/2006 | US7078051 Fatty ester food adjuvants; isomerization |
| 07/18/2006 | US7078050 White cream bacteriostats, fungicide as vehicle for drug; receptivity |
| 07/18/2006 | US7078048 A topical formulation for treating rosacea ( a facial dermatitis ) contains a combination of: an antimicrobial and at least one of non-retinoid inhibitor of one of nuclear factor-k-beta, AP-1 protein, matrix metalloproteinases, CD14 |
| 07/18/2006 | US7078047 Use of homopolymers and salts for moisturizing the skin, mucous membranes and/or keratin fibres, and/or as a moisturizer and/or emollient |
| 07/18/2006 | US7078045 Pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis |
| 07/18/2006 | US7078040 Administering to animal or man of at least one type of xanthophyll in an amount inhibiting the expression of inflammatory cytokines and chemokines in animal or man |
| 07/18/2006 | US7078026 Structured composition based on silicone oil, especially for cosmetic use |
| 07/18/2006 | US7078020 Heating antipsychotic drug to vaporize; cooling to form condensation aerosol; kit for dispensing thin coating |
| 07/18/2006 | US7078019 Heating a drug ester to vaporize; cooling to form condensation aerosol; drug delivery kit for dispensing thin coatings |
| 07/18/2006 | US7078018 Aerosol therapy; heating, vaporization, cooling, condensation; analgesics; alcoholism |
| 07/18/2006 | US7078017 Delivery of sedative-hypnotics through an inhalation route |
| 07/18/2006 | US7078016 Delivery of caffeine through an inhalation route |
| 07/18/2006 | CA2533038A1 Method of treatment for improved bioavailability |
| 07/18/2006 | CA2407416C Alkynyl phenyl heteroaromatic glucokinase activators |
| 07/18/2006 | CA2364864C New metalloprotease inhibitors, the procedure for preparing them and the pharmaceutical compounds containing them |
| 07/18/2006 | CA2356320C Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
| 07/18/2006 | CA2351833C New cyclopropanic compounds, 1,1 and 1,2-disubstitute, their preparation process and pharmaceutical compositions containing them |
| 07/18/2006 | CA2349088C Corn, callus and wart removing pads |
| 07/18/2006 | CA2341890C Oxygen-containing heterocyclic compounds |
| 07/18/2006 | CA2325781C New amino pyrrolin compounds, their preparation process and the pharmaceutical compositions therein |
| 07/18/2006 | CA2313629C Method for transferring one or more active ingredients between different phase carriers |
| 07/18/2006 | CA2309771C New substitute dimeric derivatives, their preparation process and the pharmaceutical compositions that contain them |
| 07/18/2006 | CA2307317C Tumor rejection antigen precursors, tumor rejecti0n antigens and uses thereof |
| 07/18/2006 | CA2269053C Crystals of benzimidazole derivatives and their production |
| 07/18/2006 | CA2242425C Quinazoline derivatives as vegf inhibitors |
| 07/18/2006 | CA2227938C Novel vitamin d analogues |
| 07/18/2006 | CA2224528C Stilbene compositions in the adamantyl group, compositions containing them and uses |
| 07/18/2006 | CA2216592C Benzothiophene compounds, intermediates, compositions, and methods |
| 07/18/2006 | CA2207503C Use of aminopurine antiviral agents for the treatment and prophylaxis of latent herpesvirus infections |
| 07/18/2006 | CA2152973C Phosphinic acid derivatives, their preparation and their use |
| 07/18/2006 | CA2148006C Use of non-steroidal antiestrogens for autoimmune diseases |
| 07/18/2006 | CA2132007C Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists |
| 07/13/2006 | WO2006074479A1 Process for preparing tolterodine tartrate |
| 07/13/2006 | WO2006074478A1 Substantially pure tolterodine tartrate and process for preparing thereof |
| 07/13/2006 | WO2006074445A2 Novel heteropyrrole analogs acting on cannabiniod receptors |
| 07/13/2006 | WO2006074443A2 Pde5 inhibitor compositions and methods for immunotherapy |
| 07/13/2006 | WO2006074428A2 Cxcr4 antagonists for the treatment of medical disorders |
| 07/13/2006 | WO2006074426A2 Cxcr4 antagonists for the treatment of hiv infection |
| 07/13/2006 | WO2006074419A2 Compounds for inhibiting beta-amyloid production and methods of identifying the compounds |
| 07/13/2006 | WO2006074416A1 5-amino-4-imidazolecarboxamide riboside and its nucleobase as potentiators of antifolate transport and metabolism |
| 07/13/2006 | WO2006074370A2 Agonists and antagonists of tnfrii/cd120b for treatment of immune-related diseases |
| 07/13/2006 | WO2006074359A2 Non-irritating compositions containing zinc salts |
| 07/13/2006 | WO2006074358A1 Compositions and methods relating to novel compounds and targets thereof |
| 07/13/2006 | WO2006074330A2 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| 07/13/2006 | WO2006074281A2 Inhibitors of checkpoint kinases |
| 07/13/2006 | WO2006074278A2 Compositions for treating diabetes or obesity |
| 07/13/2006 | WO2006074265A2 Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders |
| 07/13/2006 | WO2006074262A1 Ubiquitin ligase inhibitors |
| 07/13/2006 | WO2006074244A2 Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| 07/13/2006 | WO2006074227A2 HIGHLY ANTIPROLIFERATIVE, LOW-CALCEMIC, ANALOGS OF THE HORMONE 1α, 25-DIHYDROXYVITAMIN D3 WITH CARBONYL SIDE CHAINS |
| 07/13/2006 | WO2006074226A2 Prevention of thrombotic disorders with active vitamin d compounds or mimics thereof |
| 07/13/2006 | WO2006074223A2 Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof |
| 07/13/2006 | WO2006074204A2 Topical stabilized prostaglandin e compound dosage forms |
| 07/13/2006 | WO2006074166A2 Rnai agents for maintenance of stem cells |
| 07/13/2006 | WO2006074149A2 Treatment of drug-resistant proliferative disorders |
| 07/13/2006 | WO2006074147A2 Nitrogen containing bicyclic compounds and therapeutical use thereof |
| 07/13/2006 | WO2006074146A2 Use of 3-substituted-2-(diphenylmethy)-1-azabicyclo[2.2.2]octanes for treating mrg-x1 receptor mediated diseases |
| 07/13/2006 | WO2006074114A2 Compositions comprising o-acetylsalicyl derivatives of aminocarbohydrates and amino acids |
| 07/13/2006 | WO2006074094A2 Method for producing probiotically derived compounds |
| 07/13/2006 | WO2006074066A1 Non-crystalline formulation comprising clopidogrel |
| 07/13/2006 | WO2006074045A2 Immune response modifier formulations and methods |
| 07/13/2006 | WO2006074041A2 Anti-tumor compounds |
| 07/13/2006 | WO2006073973A2 Novel benzylamine derivatives as cetp inhibitors |
| 07/13/2006 | WO2006073967A1 Piperidine derivatives as prodrugs of potassium channel inhibitors |
| 07/13/2006 | WO2006073940A2 Multi-route administration of immune response modifier compounds |
| 07/13/2006 | WO2006073939A2 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate |
| 07/13/2006 | WO2006073938A2 Method for the synthesis of 3-substituted indolizine and benzoindolizine compounds |
| 07/13/2006 | WO2006073922A2 Package for cyanoacrylate adhesive |
| 07/13/2006 | WO2006073921A2 Compositions and methods for enhanced dendritic cell maturation and function |
| 07/13/2006 | WO2006073886A1 Olanzapine pamoate dihydrate |
| 07/13/2006 | WO2006073786A2 Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy |
| 07/13/2006 | WO2006073779A1 Novel omeprazole forms and related methods |
| 07/13/2006 | WO2006073729A1 Oral disintegrating dosage forms |
| 07/13/2006 | WO2006073610A2 Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them |
| 07/13/2006 | WO2006073601A2 Methods and compositions for rna interference |
| 07/13/2006 | WO2006073592A2 SALTS OF N-[2-({3R)-1-[trans-4-HYDROXY-4-(6-METHOXYPYRIDIN-3-YL)-CYCLOHEXYL]PYRROLIDINE-3-YL}AMINO)-2-OXOETHYL]-3-(TRIFLUOROMETHYL)BENZAMIDE |
| 07/13/2006 | WO2006073589A2 Cycloalkyl keto piperidine tachykinin receptor antagonists |
| 07/13/2006 | WO2006073572A2 Treatment of conditions caused by calcium abnormalities |
| 07/13/2006 | WO2006073503A1 Therapeutic calcium phosphate particles for use in inhibiting expression of a gene |
| 07/13/2006 | WO2006073457A2 Bioactive compounds and methods of uses thereof |
| 07/13/2006 | WO2006073456A2 Anti-coronavirus compounds |
| 07/13/2006 | WO2006073448A2 Methods and compositions for treating diseases and conditions associated with mitochondrial function |
| 07/13/2006 | WO2006073430A2 Therapeutic delivery system comprising a high molecular weight peg-like compound |
| 07/13/2006 | WO2006073413A1 Blood pressure reduction in salt-sensitive |
| 07/13/2006 | WO2006073396A1 Analgesic conjugates |
| 07/13/2006 | WO2006073367A1 5-thioxo-1,5-dihydro-2h-pyrrol-2-one derivatives as liver x receptor modulators |
| 07/13/2006 | WO2006073366A1 Non-anilinic derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators |
| 07/13/2006 | WO2006073365A1 Non-anilinic derivatives of isothiazol-3(2h)-thione 1,1-dioxides as liver x receptor modulators |
| 07/13/2006 | WO2006073364A1 Derivatives of isothiazol-3 (2h)-thione 1,1-dioxides as liver x receptor modulators |
| 07/13/2006 | WO2006073363A1 Derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators |
| 07/13/2006 | WO2006073361A1 Novel pyridine compounds |
| 07/13/2006 | WO2006073360A1 NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f] [1,4] THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS |
| 07/13/2006 | WO2006073359A1 Topical compositions comprising one or more of 44-thiouridine, isomaltitol and uridine |
| 07/13/2006 | WO2006073292A1 Inorganic acid salts of sibutramine |
| 07/13/2006 | WO2006073291A1 A sulphonic acid salt of sibutramine |
| 07/13/2006 | WO2006073290A1 A dicarboxylic acid salt of sibutramine |
| 07/13/2006 | WO2006073285A1 Use of lignan compounds for treating or preventing inflammatory disease |
| 07/13/2006 | WO2006073202A1 METHOD OF TUMOR SUPPRESSION AND EVALUATION OF ANTICANCER AGENT BASED ON GSK3β INHIBITORY EFFECT |